182 320
Table 2 – Study characteristics
Study
Reader
MRI
First author
(year)
Design Consecutive
enrollment
Reference
standard
MRI–
reference
standard
interval
No. of
readers
Experience
(yr)
Blinding Magnet
strength
(T)
Vendor
Model
Endorectal
coil
PI-RADSv2
application
Cutoff
values
Localization Type of
analysis
Outcome
assessed
Definition
of csPCa
Auer
(2016)
[16]
Retrospective
Yes RP
NR
1
>
5
Yes 3
Siemens Skyra
No Strict
4
Whole Lesion Any +
csPCa
GS 7
(4 + 3)
Baldisserotto
(2016)
[17]
Retrospective
Yes STRUSGB + targeted
MRI–TRUS biopsy
(cognitive) or RP
NR
2
Independent
>
10/1
Yes 3
GE
SignaHDxt
No Strict
3, 4 Whole Patient Any
De Visschere
(2017)
[18]
Retrospective
NR STRUSGB or RP
NR
NR NR
NR 3
Siemens Trio
No Strict
4
Whole Patient csPCa GS 7,
0.5 cc,
or EPE
El-Samei
(2016)
[19]NR
NR Targeted MRI–TRUS
biopsy
2 wk
NR NR
NR 1.5
Phillips
Gyroscan
Yes Strict
4
Whole Lesion Any
Feng
(2016)
[20]
Retrospective
Yes STRUSGB + targeted
MRI–TRUS biopsy
(cognitive)
1–35 d
2
Consensus
5/4
Yes 3
Siemens Skyra
No Strict
4
PZ, TZ Patient Any
Kasel-Seibert
(2016)
[21]
Retrospective
NR Targeted MRGB
7 d
2
Independent
10/
<
1
Yes 1.5
Siemens Avanto
Yes Strict
4
Whole Lesion Any +
csPCa
GS 7
Lin
(2016)
[22]
Retrospective
NR RP
6 mo
2
Independent
12/5
Yes
a
1.5
Phillips
Achieva
Yes Strict
3, 4 Whole Lesion csPCa GS 7 and
>
0.5 cc
Martorana
(2016)
[23]
Retrospective
Yes TTB + targeted
MRI–TRUS biopsy
30–78
2
Consensus
4/4
Yes 1.5
Phillips
Achieva
Yes Strict
3, 4 Whole Lesion Any GS 7,
>
0.5 cc,
or EPE
Mertan
(2016)
[24]
Prospective
Yes STRUSGB + targeted
MRI–TRUS biopsy
NR
1
>
8
Yes 3
Phillips
Achieva
Yes Strict
4
PZ, TZ Lesion Any +
csPCa
GS 7
Muller
(2015)
[25]
Retrospective
Yes STRUSGB + targeted
MRI–TRUS biopsy
6 wk
5
Independent
12/7/1/1/0.5 Yes 3
Phillips
Achieva
Yes Strict
4
PZ, TZ Lesion Any GS 7
(4 + 3)
Park
(2016)
[26]
Retrospective
Yes RP
21–48
2
Independent
14/3
Yes
a
3Phillips
Achieva
No Strict
4
Whole Patient csPCa GS 7,
0.5 cc,
or EPE
Park
(2016)
[27]
Retrospective
NR RP
NR
2
Independent
9/4
Yes 3
GE, Philips,
Siemens
DiscoveryMR750,
Achieva, Trio
No Strict
4
Whole Patient csPCa GS 7,
0.5 cc,
or EPE
Polanec
(2016)
[28]
Retrospective
Yes Targeted MRGB
NR
2
Independent
NR/NR
Yes 3
Siemens Trio
No Strict
4
PZ, TZ Lesion Any
Rastinehad
(2015)
[29]
Prospective
NR STRUSGB + targeted
MRI–TRUS biopsy
NR
3
Consensus
NR
Yes 3
Siemens Verio
Yes Calculated
b
3, 4 Whole Patient Any +
csPCa
Epstein’s
criteria
c
for
systematic
and GS 7
or
>
0.5 cc
for targeted
biopsy
Rosenkrantz
(2016)
[30]
Retrospective
NR Targeted MRI–TRUS
biopsy
NR
2
Independent
8/3
NR 3
Siemens biobraphmMR/
Prisma/Skyra/Trio
No Strict
4
PZ, TZ Lesion csPCa GS 7
Stanzione
(2016)
[31]Prospective
NR STRUSGB ( targeted
TRUSGB)
20–30 d
2
Independent
14/10
Yes 3
Siemens Trio
No Strict
4
PZ
Patient Any
Tan
(2016)
[32]
Retrospective
Yes Targeted MRGB
NR
3
consensus
16/10
NR 3
Siemens Skyra, Trio, Verio
No Strict
3
Whole Lesion Any +
csPCa
GS 7
Tewes
(2016)
[33]
Retrospective
Yes Targeted MRGB
NR
2
Independent
5/2
Yes 3
Siemens Skyra
No Strict
3
d
PZ, TZ Patient Any
Washino
(2017)
[34]Retrospective
NR TTB + targeted
MRI–TRUS biopsy
(cognitive)
0.5–1.6 mo
1
14
Yes 1.5 or 3 Toshiba Excelart Vantage/
Vantage Titan 3T
No Strict
3
Whole Patient csPCa GS 7 or
maximum
core length
4 mm
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 1 7 7 – 1 8 8
182